Mary Ann Liebert: Immunomodulatory Nanoparticles Prevent Secondary Damage After Traumatic Brain Injury
November 22, 2024
November 22, 2024
NEW ROCHELLE, New York, Nov. 22 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A new study published in the peer-reviewed Journal of Neurotrauma shows that intravenous administration of immunomodulatory nanoparticles after traumatic brain injury (TBI) can limit the development of an inflammatory cascade that typically leads to substantial secondary damage. The nanoparticles limited inflammatory cell infiltration and reduced both behavioral decline and lesion si . . .
A new study published in the peer-reviewed Journal of Neurotrauma shows that intravenous administration of immunomodulatory nanoparticles after traumatic brain injury (TBI) can limit the development of an inflammatory cascade that typically leads to substantial secondary damage. The nanoparticles limited inflammatory cell infiltration and reduced both behavioral decline and lesion si . . .